Exisulind Significantly Inhibits Tumor Growth With Minimal Side Effects

Publication
Article
OncologyONCOLOGY Vol 15 No 12
Volume 15
Issue 12

The results of a clinical study demonstrating that exisulind (Aptosyn) slows tumor growth in men with advanced prostate cancer was published in the September 2001 issue of The Journal of Urology. The study is the first to show the significant

The results of a clinical study demonstrating thatexisulind (Aptosyn) slows tumor growth in men with advanced prostate cancer waspublished in the September 2001 issue of The Journal of Urology. The study isthe first to show the significant effect of this new class of drugs that maystabilize progressive, recurrent disease in patients with advanced prostatecancer. Previous studies in mice showed that exisulind inhibited the growth ofprostate cancer by 80% to 90%.

"These results suggest that exisulind may delay disease progression inmen with recurrent prostate cancer," said Dr. Erik Goluboff, assistantprofessor of urology at Columbia University College of Physicians and Surgeons,director of urology at The Allen Pavilion of New York-Presbyterian Hospital, andthe principal investigator of the trial. "This will subsequently prolongthe time period between postsurgical PSA rise and the need for androgendeprivation therapies."

PSA Levels Stabilized

For 12 months, the trial followed 96 prostate cancer patients who already hadtheir prostate glands removed. All had rising prostate-specific antigen (PSA)levels indicating recurrent disease. Half received exisulind, and half weregiven a placebo. The researchers measured the drug’s ability to slow or haltdisease progression by following patient’s PSA levels.

Imaging tests were performed before and after the study, which was funded byCell Pathways Inc, developer of the drug. All the men were classified into riskgroups with no statistical difference in age, race, and weight. The study showeda significant decrease in the rate at which PSA levels rose in patients givenexisulind compared with placebo. However, Dr. Goluboff cautioned that moreresearch needs to be conducted to determine the long-term effects in thesepatients and in other groups of patients with prostate cancer.

Recent Videos
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Related Content